Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Single Agent Depsipeptide (FK228; NSC 630176; IND 51,810) in Patients With Unresectable Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

NCT00084682 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT00084682
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00084682 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Single Agent Depsipeptide (FK228; NSC 630176; IND 51,810) in Patients With Unresectable Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2005
Completion date
March 31, 2012
Enrollment
14 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

stage iv squamous cell carcinoma of the hypopharynx, stage iv squamous cell carcinoma of the larynx, stage iv squamous cell carcinoma of the lip and oral cavity, stage iv squamous cell carcinoma of the oropharynx